Regenxbio RGNX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$90.05M-1,580% | -$67.15M-31.2% | -$61.94M-3.9% | -$70.87M-33.7% | $6.08M+110% | ||
| $3.86M-2.5% | $3.87M-3.8% | $3.89M-1.9% | $3.91M-3.6% | $3.96M-5.4% | ||
| $8.62M+0.9% | $8.38M-12.2% | $9M-9.0% | $8.65M-8.3% | $8.54M-11.1% | ||
| -$18.25M-1,061% | $561K+107% | $6.31M— | $2.36M— | -$1.57M+82.9% | ||
| $349K+110% | -$1.86M— | —— | —— | -$3.65M-143% | ||
| -$16.73M-15.5% | $45K+100% | $2.75M— | $11.92M— | -$14.49M+15.2% | ||
| $900K+189% | $345K+204% | $2.39M— | -$1.11M+12.8% | -$1.01M-71.7% | ||
| -$16K+99.5% | -$10K— | -$16K— | -$16K— | -$2.96M-6.9% | ||
| -$19K-290% | -$537K+61.2% | -$48K— | -$22K— | $10K-85.9% | ||
| -$700K-102% | —— | —— | —— | $39.77M+29,559% | ||
| -$384K-119% | —— | $2.17M— | —— | $2.03M+318% | ||
| $1.31M-41.3% | -$6.24M+33.0% | -$7K— | $3.35M— | $2.24M-67.2% | ||
| -$76.19M-327% | -$52.29M-65.3% | -$55.96M-38.0% | -$49.34M-8.5% | $33.63M+161% | ||
| $1.24M+20.6% | $508K-52.9% | $491K+50.6% | $391K-17.5% | $1.02M+83.8% | ||
| $70.59M+57.8% | —— | —— | -$140.44M— | $44.74M+239% | ||
| $146K-2.7% | $90K+137% | $0-100% | $78K-59.4% | $150K-83.0% | ||
| -$13.64M-135% | —— | —— | $139.23M— | -$5.79M-105% | ||
| -$19.24M-127% | -$24.34M-2,777% | —— | —— | $72.58M-7.5% | ||
| —— | $71.25K+496% | $71.25K+496% | $71.25K+496% | $71.25K+496% | ||
| $879K-17.9% | $1.23M+10.0% | $1.82M+38.5% | $1.36M+9.1% | $1.07M+129% | ||
| $349K+110% | -$1.86M— | —— | —— | -$3.65M-143% | ||
| -$16.73M-15.5% | $45K+100% | $2.75M— | $11.92M— | -$14.49M+15.2% | ||
| -$700K-102% | —— | —— | —— | $39.77M+29,559% | ||
| -$2.53M-13.8% | -$3.01M-45.7% | -$1.22M+38.7% | -$2.18M-9.8% | -$2.22M-8.7% | ||
| -$1.71M-4.1% | -$1.66M-3.4% | -$1.68M-6.9% | -$1.67M-12.5% | -$1.64M-7.2% | ||
| $1.31M-41.3% | -$6.24M+33.0% | -$7K— | $3.35M— | $2.24M-67.2% | ||
| -$384K-119% | —— | $2.17M— | —— | $2.03M+318% | ||
| $3.75M+1,455% | $5.11M-10.2% | $5.31M+1,108% | $2.77M+487% | -$277K-140% | ||
| -$19K-290% | -$537K+61.2% | -$48K— | -$22K— | $10K-85.9% | ||
| $648K+111% | —— | $741K-5.0% | —— | $307K-25.3% | ||
| $13.38M+139% | $9.65M+26.8% | $7.59M-35.3% | $5.26M— | $5.59M— | ||
| $828K+62.4% | —— | $123K— | —— | $510K-44.0% | ||
| $553K+211% | —— | —— | —— | $178K+110% | ||
| $148K+3.5% | —— | —— | —— | $143K+158% | ||
| —— | $124.75K-20.5% | $124.75K-20.5% | $124.75K-20.5% | $124.75K-20.5% | ||
| —— | $8.03M+390% | $8.03M+390% | $8.03M+390% | $8.03M+390% | ||
| —— | $71.25K+496% | $71.25K+496% | $71.25K+496% | $71.25K+496% | ||
| -$77.42M-337% | -$52.8M-61.4% | -$56.45M-38.1% | -$49.73M-8.2% | $32.61M+158% | ||
| -$77.42M-337% | -$52.8M-61.4% | -$56.45M-38.1% | -$49.73M-8.2% | $32.61M+158% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Regenxbio generate?
- Regenxbio (RGNX) generated -$233.8M in operating cash flow over the trailing twelve months.
- What is Regenxbio's free cash flow?
- After $2.6M of capital expenditures, Regenxbio's free cash flow was -$236.4M over the trailing twelve months, down 171.9% year over year.
- Where does Regenxbio's cash flow data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
